MA43605B1 - Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci - Google Patents
Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ciInfo
- Publication number
- MA43605B1 MA43605B1 MA43605A MA43605A MA43605B1 MA 43605 B1 MA43605 B1 MA 43605B1 MA 43605 A MA43605 A MA 43605A MA 43605 A MA43605 A MA 43605A MA 43605 B1 MA43605 B1 MA 43605B1
- Authority
- MA
- Morocco
- Prior art keywords
- isoquinolin
- carboxamides
- preparation
- disease
- treatment
- Prior art date
Links
- KKSZSACCVDIWIE-UHFFFAOYSA-N isoquinoline-3-carboxamide Chemical class C1=CC=C2C=NC(C(=O)N)=CC2=C1 KKSZSACCVDIWIE-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 1
- -1 isoquinoline compound Chemical class 0.000 abstract 1
- 150000002537 isoquinolines Chemical class 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328210P | 2016-04-27 | 2016-04-27 | |
| PCT/US2017/029797 WO2017189823A2 (en) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides and preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43605A1 MA43605A1 (fr) | 2020-04-30 |
| MA43605B1 true MA43605B1 (fr) | 2020-10-28 |
Family
ID=60157342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43605A MA43605B1 (fr) | 2016-04-27 | 2017-04-27 | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10508099B2 (enExample) |
| EP (2) | EP3448838B1 (enExample) |
| JP (1) | JP7023243B2 (enExample) |
| KR (1) | KR102399206B1 (enExample) |
| CN (1) | CN109311819B (enExample) |
| AR (1) | AR108326A1 (enExample) |
| AU (1) | AU2017258187B2 (enExample) |
| BR (1) | BR112018072190A2 (enExample) |
| CA (1) | CA3022044A1 (enExample) |
| CL (2) | CL2018003050A1 (enExample) |
| CO (1) | CO2018012655A2 (enExample) |
| IL (1) | IL262495B (enExample) |
| MA (1) | MA43605B1 (enExample) |
| MX (1) | MX386319B (enExample) |
| PE (1) | PE20190260A1 (enExample) |
| PH (1) | PH12018502259A1 (enExample) |
| RU (1) | RU2018141379A (enExample) |
| SG (2) | SG10201914127PA (enExample) |
| WO (1) | WO2017189823A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151501A1 (es) | 2012-12-21 | 2015-11-08 | Epizyme Inc | Inhibidores de prmt5 y sus usos |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| JP7160688B2 (ja) * | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 |
| AU2018243770A1 (en) | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
| US11149022B2 (en) * | 2017-10-17 | 2021-10-19 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019079626A1 (en) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
| WO2019084496A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE |
| WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
| US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
| US10975057B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
| JP2021529161A (ja) | 2018-06-18 | 2021-10-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール |
| JP2021528405A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| EP3807251B1 (en) | 2018-06-18 | 2022-09-07 | Janssen Pharmaceutica NV | Phenyl and pyridinyl substituted imidazoles as modulators of roryt |
| JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
| TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| CN114401946A (zh) * | 2019-09-05 | 2022-04-26 | 鲁南制药集团股份有限公司 | Magl抑制剂及其制备方法、用途 |
| IL299080A (en) * | 2020-06-19 | 2023-02-01 | Univ Vanderbilt | Arylsulfonyl history and their use as M5 muscarinic acetylcholine receptor inhibitors |
| WO2022093881A1 (en) * | 2020-10-29 | 2022-05-05 | Merck Sharp & Dohme Corp. | N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| TW202302565A (zh) * | 2021-02-19 | 2023-01-16 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
| WO2023055679A1 (en) * | 2021-10-01 | 2023-04-06 | Merck Sharp & Dohme Llc | C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| WO2023107714A2 (en) * | 2021-12-10 | 2023-06-15 | Prothena Biosciences Limited | Methods for treating neurological disorders |
| TW202506660A (zh) * | 2023-04-27 | 2025-02-16 | 美商塞普特納公司 | Mrgprx2拮抗劑及其使用方法 |
| KR20240162928A (ko) | 2023-05-09 | 2024-11-18 | 주식회사 베노바이오 | Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| ES2131463B1 (es) * | 1997-04-08 | 2000-03-01 | Lilly Sa | Derivados de ciclopropilglicina con propiedades farmaceuticas. |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| GB0310867D0 (en) | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2008537684A (ja) | 2005-01-24 | 2008-09-25 | ニューロシステック コーポレイション | 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法 |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| AU2008287435B2 (en) | 2007-08-15 | 2013-05-16 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| JP2013501792A (ja) | 2009-08-10 | 2013-01-17 | サミュメッド リミテッド ライアビリティ カンパニー | Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用 |
| DK2987487T3 (da) | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
| RU2012146246A (ru) * | 2010-03-31 | 2014-05-10 | Актелион Фармасьютиклз Лтд | Антибактериальные производные изохинолин-3-илмочевины |
| EA026115B1 (ru) | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
| PT2755483T (pt) | 2011-09-14 | 2019-02-18 | Samumed Llc | Indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização de wnt/β-catenina |
| WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
| US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
| MA39763A (fr) | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| EP3813826A4 (en) | 2018-06-26 | 2022-07-06 | BioSplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
-
2017
- 2017-04-26 AR ARP170101056A patent/AR108326A1/es unknown
- 2017-04-27 EP EP17790411.7A patent/EP3448838B1/en active Active
- 2017-04-27 EP EP21181038.7A patent/EP3943086A1/en not_active Withdrawn
- 2017-04-27 SG SG10201914127PA patent/SG10201914127PA/en unknown
- 2017-04-27 PE PE2018002175A patent/PE20190260A1/es unknown
- 2017-04-27 AU AU2017258187A patent/AU2017258187B2/en not_active Ceased
- 2017-04-27 BR BR112018072190-5A patent/BR112018072190A2/pt not_active IP Right Cessation
- 2017-04-27 JP JP2018556921A patent/JP7023243B2/ja active Active
- 2017-04-27 RU RU2018141379A patent/RU2018141379A/ru unknown
- 2017-04-27 CA CA3022044A patent/CA3022044A1/en active Pending
- 2017-04-27 US US15/498,990 patent/US10508099B2/en active Active
- 2017-04-27 MA MA43605A patent/MA43605B1/fr unknown
- 2017-04-27 SG SG11201809310PA patent/SG11201809310PA/en unknown
- 2017-04-27 KR KR1020187034080A patent/KR102399206B1/ko active Active
- 2017-04-27 WO PCT/US2017/029797 patent/WO2017189823A2/en not_active Ceased
- 2017-04-27 CN CN201780037470.7A patent/CN109311819B/zh active Active
- 2017-04-27 MX MX2018013173A patent/MX386319B/es unknown
-
2018
- 2018-03-19 US US15/925,157 patent/US10287267B2/en active Active
- 2018-04-03 US US15/943,864 patent/US10556885B2/en active Active
- 2018-10-21 IL IL262495A patent/IL262495B/en unknown
- 2018-10-23 PH PH12018502259A patent/PH12018502259A1/en unknown
- 2018-10-26 CL CL2018003050A patent/CL2018003050A1/es unknown
- 2018-11-23 CO CONC2018/0012655A patent/CO2018012655A2/es unknown
-
2019
- 2019-07-24 CL CL2019002067A patent/CL2019002067A1/es unknown
- 2019-12-26 US US16/727,053 patent/US11174244B2/en active Active
-
2021
- 2021-10-06 US US17/495,281 patent/US11673881B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43605B1 (fr) | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci | |
| MA43619A1 (fr) | Isoquinolin-3-yl carboxamides et préparation et utilisation de ceux-ci | |
| MA37450A1 (fr) | Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques | |
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| TN2009000551A1 (fr) | Nouveaux composes chimiques | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| MA47392A1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
| MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MA40224B1 (fr) | Anticorps se liant aux protofibrilles ass améliorés | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA41758B1 (fr) | Procédés de traitement de l'infertilité | |
| MA46548B1 (fr) | Fsh pour le traitement de l'infertilité | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| EP3723768A4 (en) | COMPOUNDS FOR TREATMENT AND PREVENTION OF EXTRACELLULAR HISTONE-MEDIATED PATHOLOGIES | |
| MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| MA31198B1 (fr) | Nouvelle forme dosifiee | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| MX2020005238A (es) | Compuestos novedosos como inhibidores mpges-1. | |
| MA44660B1 (fr) | (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille | |
| MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer |